Enzyme-based visualization of receptor-ligand binding in tissues

Laboratory Investigation

Volumn 86, Issue 5, 2006, Pages 517-525

  Montet, Xavier ^a   Yuan, Hushan ^b   Weissleder, Ralph ^b   Josephson, Lee ^b  

^a Geneva Hospital   (Switzerland)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Antifluorescein; Binding; Fluorescein; Receptor activity; Tissue microarray

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; ASIALOGLYCOPROTEIN RECEPTOR; BOMBESIN RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUORESCEIN; FOLATE RECEPTOR; HEMATOXYLIN; HORSERADISH PEROXIDASE; INTEGRIN; INTEGRIN RECEPTOR; NEUROPEPTIDE Y RECEPTOR;

ANIMAL TISSUE; ARTICLE; CELL STRUCTURE; HUMAN; HUMAN CELL; ISOTOPE LABELING; LIGAND BINDING; MICROSCOPY; MONOLAYER CULTURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; RECEPTOR BINDING; RECEPTOR INTRINSIC ACTIVITY; TISSUE MICROARRAY;

AMINO ACID SEQUENCE; ANIMALS; CELL LINE; COLON; FLUORESCEIN; HAPTENS; HORSERADISH PEROXIDASE; HUMANS; IMMUNOASSAY; LIGANDS; LIVER; MICE; MOLECULAR SEQUENCE DATA; PANCREAS; PEPTIDES; RATS; RECEPTORS, CELL SURFACE; TISSUE ARRAY ANALYSIS;

EID: 33646126954     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.3700404     Document Type: Article

References (36)

1. Stumpf WE. Drug localization and targeting with receptor microscopic autoradiography. J Pharmacol Toxicol Methods 2005;51:25-40.
2. Dumont Y, Chabot JG, Quirion R. Receptor autoradiography as mean to explore the possible functional relevance of neuropeptides: focus on new agonists and antagonists to study natriuretic peptides, neuropeptide Y and calcitonin gene-related peptides. Peptides 2004;25:365-391.
3. Reubi JC, Waser B, Horisberger U, et al. In vitro autoradiographic and in vivo scintigraphic localization of somatostatin receptors in human lymphatic tissue. Blood 1993;82:2143-2151.
4. Kelly KA, Reynolds F, Weissleder R, et al. Fluorescein isothiocyanate-hapten immunoassay for determination of peptide-cell interactions. Anal Biochem 2004;330:181-185.
5. Stupack DG, Cheresh DA. Integrins and angiogenesis. Curr Top Dev Biol 2004;64:207-238.
6. Westlin WF. Integrins as targets of angiogenesis inhibition. Cancer J 2001;7(Suppl 3):S139-S143.
7. Byzova TV, Plow EF. Activation of alphaVbeta3 on vascular cells controls recognition of prothrombin. J Cell Biol 1998;143:2081-2092.
8. Smith CJ, Volkert WA, Hoffman TJ. Gastrin releasing peptide (GRP) receptor targeted radiopharmaceuticals: a concise update. Nucl Med Biol 2003;30:861-868.
9. Sano H, Feighner SD, Hreniuk DL, et al. Characterization of the bombesin-like peptide receptor family in primates. Genomics 2004;84:139-146.
10. Birn H, Nielsen S, Christensen EI. Internalization and apical-to-basolateral transport of folate in rat kidney proximal tubule. Am J Physiol 1997;272:F70-F78.
11. Schwartz AL. The hepatic asialoglycoprotein receptor. CRC Crit Rev Biochem 1984;16:207-233.
12. Kokudo N, Vera DR, Makuuchi M. Clinical application of TcGSA. Nucl Med Biol 2003;30:845-849.
13. Rettenbacher M, Reubi JC. Localization and characterization of neuropeptide receptors in human colon. Naunyn Schmiedebergs Arch Pharmacol 2001;364:291-304.
14. Ferrier L, Segain JP, Bonnet C, et al. Functional mapping of NPY/PYY receptors in rat and human gastro-intestinal tract. Peptides 2002;23:1765-1771.
15. Cox HM, Tough IR. Neuropeptide Y, Y1, Y2 and Y4 receptors mediate Y agonist responses in isolated human colon mucosa. Br J Pharmacol 2002;135:1505-1512.
16. Pedrazzini T, Pralong F, Grouzmann E. Neuropeptide Y: the universal soldier. Cell Mol Life Sci 2003;60:350-377.
17. Zhou J, Chen J, Mokotoff M, et al. Targeting gastrin-releasing peptide receptors for cancer treatment. Anticancer Drugs 2004;15:921-927.
18. Jensen RT, Coy DH, Saeed ZA, et al. Interaction of bombesin and related peptides with receptors on pancreatic acinar cells. Ann NY Acad Sci 1988;547:138-149.
19. Markwalder R, Reubi JC. Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. Cancer Res 1999;59:1152-1159.
20. Fleischmann A, Laderach U, Friess H, et al. Bombesin receptors in distinct tissue compartments of human pancreatic diseases. Lab Invest 2000;80:1807-1817.
21. Nock BA, Nikolopoulou A, Galanis A, et al. Potent bombesin-like peptides for GRP-receptor targeting of tumors with 99mTc: a preclinical study. J Med Chem 2005;48:100-110.
22. Leamon CP, Reddy JA. Folate-targeted chemotherapy. Adv Drug Deliv Rev 2004;56:1127-1141.
23. Sudimack J, Lee RJ. Targeted drug delivery via the folate receptor. Adv Drug Deliv Rev 2000;41:147-162.
24. Carraway III KL, Koland JG, Cerione RA. Visualization of epidermal growth factor (EGF) receptor aggregation in plasma membranes by fluorescence resonance energy transfer. Correlation of receptor activation with aggregation. J Biol Chem 1989;264:8699-8707.
25. Chatelier RC, Ashcroft RG, Lloyd CJ, et al. Binding of fluoresceinated epidermal growth factor to A431 cell sub-populations studied using a model-independent analysis of flow cytometric fluorescence data. EMBO J 1986;5:1181-1186.
26. Watanabe T, Yasumura S, Shibata H, et al. Biotin status and its correlation with other biochemical parameters in the elderly people of Japan. J Am Coll Nutr 1998;17:48-53.
27. Baker H. Assessment of biotin status: clinical implications. Ann NY Acad Sci 1985;447:129-132.
28. Hollenberg NK, Graves SW. Endogenous sodium pump inhibition: current status and therapeutic opportunities. Prog Drug Res 1996;46:9-42.
29. Muller JD, Nienhaus GU, Tetin SY, et al. Ligand binding to anti-fluorescyl antibodies: stability of the antigen binding site. Biochemistry 1994;33:6221-6227.
30. Bates RM, Ballard DW, Voss Jr EW. Comparative properties of monoclonal antibodies comprising a high-affinity anti-fluorescyl idiotype family. Mol Immunol 1985;22:871-877.
31. Voss Jr EW, Eschenfeldt W, Root RT. Fluorescein: a complete antigenic group. Immunochemistry 1976;13:447-453.
32. Reile H, Armatis PE, Schally AV. Characterization of high-affinity receptors for bombesin/gastrin releasing peptide on the human prostate cancer cell lines PC-3 and DU- 145: internalization of receptor bound 125I-(Tyr4) bombesin by tumor cells. Prostate 1994;25:29-38.
33. Maina T, Nock BA, Zhang H, et al. Species differences of bombesin analog interactions with GRP-R define the choice of animal models in the development of GRP-R-targeting drugs. J Nucl Med 2005;46:823-830.
34. Filmus J, Pollak MN, Cailleau R, et al. MDA-468, a human breast cancer cell line with a high number of epidermal growth factor (EGF) receptors, has an amplified EGF receptor gene and is growth inhibited by EGF. Biochem Biophys Res Commun 1985;128:898-905.
35. Falette N, Frappart L, Lefebvre MF, et al. Increased epidermal growth factor receptor level in breast cancer cells treated by 1,25-dihydroxyvitamin D3. Mol Cell Endocrinol 1989;63:189-198.
36. Imai Y, Leung CK, Friesen HG, et al. Epidermal growth factor receptors and effect of epidermal growth factor on growth of human breast cancer cells in long-term tissue culture. Cancer Res 1982;42:4394-4398.